BLOG

Seven Corners Issues Review of Allergan (AGN) Q2 and 1H 2017 Results, Reiterates Sell Rating, Sees 50% Downside in Stock

August 20, 2017

Seven Corners has published a writeup regarding Allergan's 2nd quarter and 1st half 2017 financial results, regarding which we note the following:

  • Allergan’s non-GAAP financial metrics continue to mislead.

  • In the writeup we review Allergan’s Q2 and 1H 2017 financial results.

  • GAAP results highlight clearly declining operational performance.

  • We reiterate our $117 target share price for Allergan. 

To find a PDF containing our full AGN writeup, please visit our Research section (link here).

Please reload

Featured Posts

CCUR Holdings: 2019 Annual Meeting Trip Report

November 11, 2019

1/7
Please reload

Recent Posts
Please reload

Archive
Please reload

50 Vanderbilt Ave, 4th Fl, New York, New York 10017       

info@sevencornerscapital.com

Content © 2016 Seven Corners Capital Management, LLC. All rights reserved.

  • RSS Social Icon
  • Twitter Social Icon
  • SA